Impact of patent expiries for key products on growth
First written in FY2016. 13 of 21 entries say "Restated". Latest entry: 2026-04-27.
Astellas Pharma moved to the "Worse" side of this theme in 2026, 6 years after the typical company in this theme (2020).
The whole theme swung hardest in 2017: 4 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Worsened".
- FY2025-H1MaterialisedAnnual report
「These measures offset the decline in sales resulting from the impact of generic products for overactive bladder treatment Mirabegron in the United States.」
The decline in sales resulting from generic competition for Mirabegron in the United States was reflected in actual results following the expiry of key product patents and exclusive periods. - FY2024RestatedAnnual report
「We will continue to establish a structure capable of overcoming the expiry of XTANDI's exclusive marketing period.」
Continues to identify the risk of declining sales following the expiry of XTANDI's exclusive marketing period in the latter half of the 2020s as an issue requiring a response structure. - FY2024-Q3RestatedAnnual report
「ACP is expected to serve as one of the pillars generating revenue, together with fezolinetant and PADCEV, and to offset the decline in sales following the expiry of XTANDI's exclusive period in the latter half of the 2020s.」
Reconfirms the risk of declining sales following the expiry of XTANDI's exclusive period in the latter half of the 2020s and the role of follow-on products in offsetting it. - FY2024-Q1RestatedAnnual report
「ACP is expected to serve as one of the pillars generating revenue, together with fezolinetant and PADCEV, and to offset the decline in sales following the expiry of XTANDI's exclusive period in the latter half of the 2020s.」
Reiterates the future risk of declining sales following the expiry of XTANDI's exclusive period in the latter half of the 2020s. - FY2022-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
Reconfirms that there were no material changes to existing business or other risks, including the impact of patent-term expiries for key products on growth. The quotation itself does not quantify or demonstrate materialization of the issue. - FY2021-Q3MaterialisedAnnual report
「Sales of Vesicare were ¥24.7 billion, down 31.8% year on year, mainly because they continued to be affected by the launch of generic products following the expiry of its exclusive marketing period in Europe.」
The impact following the expiry of Vesicare's exclusive marketing period in Europe continued, with sales down 31.8% year on year. The risk was reflected in quantified results. - FY2021-Q2MaterialisedAnnual report
「However, revenue declined due to the expiry of the exclusive marketing periods for Vesicare, an OAB treatment in Europe, and Celecox, an anti-inflammatory and analgesic in Japan, as well as the expiration of the sales agreements for Symbicort, human vaccines of KM Biologics and the Micardis family of antihypertensive treatments.」
States that the expiry of exclusive marketing periods for Vesicare and Celecox actually occurred and, together with the termination of sales agreements, contributed to the decline in revenue. - FY2021-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
Reconfirms that there were no material changes to existing business or other risks, including the impact of patent-term expiries for key products on growth. - FY2020-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative third-quarter period, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
Reconfirms that there were no material changes to existing business or other risks, including the risk of patent-term expiries for key products. - FY2020-Q1MaterialisedAnnual report
「Although sales were affected by the expiry of the exclusive marketing periods for Vesicare, a treatment for overactive bladder (OAB), and Tarceva, an anticancer drug, revenue increased owing to higher sales of key products and the growth of new products.」
States that the impact of the expiry of exclusive marketing periods for key products was realized in the results for Vesicare and Tarceva. - FY2019RestatedAnnual report
「By steadily implementing Management Plan 2018, which began in fiscal 2019, we aim to overcome the impact on our results of patent-term expiries for key products from 2019 through 2020 and return to a medium- to long-term trend of profit growth.」
Continues to position the impact of patent-term expiries for key products from 2019 through 2020 as a challenge. - FY2019-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative third-quarter period, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
Reconfirms that there were no material changes to existing business or other risks, including the risk of patent-term expiries for key products. - FY2019-Q1RestatedAnnual report
「There were no newly arising business or other risks during the cumulative first-quarter period, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
Reconfirms that there were no material changes to existing business or other risks, including the risk of patent-term expiries for key products. - FY2018SoftenedAnnual report
「Going forward, to overcome the impact on our results of the expiry of patent terms for key products that we will face from 2019 through 2020 and achieve sustainable growth」
The period in which the risk from patent-term expiries for key products begins is described as 2019 through 2020 rather than 2018 through 2020, narrowing the period covered. - FY2018-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative third-quarter period, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
Reconfirms that there were no material changes to existing business or other risks, including the risk of patent expiries for key products. - FY2018-Q1RestatedAnnual report
「There were no newly arising business or other risks during the cumulative first-quarter period, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
Reconfirms that there were no material changes to existing business or other risks, including the risk of patent expiries for key products. - FY2017RestatedAnnual report
「To overcome the impact of patent expiries for key products that we will face from 2018 through 2020 and achieve long-term growth, we will continue to address three strategic priorities: maximizing product value, creating innovation and pursuing Operational Excellence.」
Continues to position patent expiries for key products from 2018 through 2020 as a challenge to long-term growth. - FY2017-Q1RestatedAnnual report
「There were no newly arising business or other risks during the cumulative first-quarter period, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
States that there were no material changes to the business or other risks described in the previous fiscal year. - FY2016First statedAnnual report
「To overcome the impact of patent expiries for key products that we will face from 2018 through 2020 and achieve long-term growth」
Explicitly identifies patent expiries for key products from 2018 through 2020 as a challenge to long-term growth.